Citations

Clear

1020 citation(s) found for "Perez, EA".

The cancer‐related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis
Villanueva, Francisco , Briceño, Pedro, Varela, Nelson , Stevenson, A.E., Jerez, Sofía , Tempio, Fabián , Chnaiderman, Jonás , Perez, Carola, Villarroel, Milena , Concha, Emma , Khani, Farzaneh , Thaler, Roman , Salazar‐Onfray, Flavio , Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J , Galindo, Mario A , Araya, Hector, Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | January 14, 2019 | Volume: 234 | Issue: 8 | Pages: 13659-13679

10.1002/jcp.28046 | PMID 30637720 Get It

Abstract Osteosarcomas are bone tumors that frequently metastasize to the lung. Aberrant expression of the transcription factor, runt‐related transcription factor 2 (RUNX2), is a key pathological feature in osteosarcoma and associated with loss of p53 and miR‐34 expression. Elevated RUNX2 may transcriptionally activate genes mediating tumor progression and metastasis, including the RUNX2 target gene osteopontin ( OPN/SPP1 ). This gene encodes a secreted matricellular protein produced by osteoblasts to regulate bone matrix remodeling and tissue calcification. Here we investigated whether and how the RUNX2/OPN axis regulates lung metastasis of osteosarcoma. Importantly, RUNX2 depletion attenuates lung metastasis of osteosarcoma cells in vivo. Using next‐generation RNA‐sequencing, protein‐based assays, as well as the loss‐ and gain‐of‐function approaches in selected osteosarcoma cell lines, we show that osteopontin messenger RNA levels closely correlate with RUNX2 expression and that RUNX2 controls the levels of secreted osteopontin. Elevated osteopontin levels promote heterotypic cell–cell adhesion of osteosarcoma cells to human pulmonary microvascular endothelial cells, but not in the presence of neutralizing antibodies. Collectively, these findings indicate that the RUNX2/OPN axis regulates the ability of osteosarcoma cells to attach to pulmonary endothelial cells as a key step in metastasis of osteosarcoma cells to the lung.
An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Feldman, Andew L., Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Doǧan, Ahmet , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e22171-e22171

10.1200/jco.2014.32.15_suppl.e22171 Get It

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
Kottschade, Lisa A. , Halyard, Michele Y. , Sloan, Jeff A. , Flickinger, Lynn M. , Harris, Lyndsay N. , Le‐Lindqwister, Nguyet, Boyle, Frances , McCaskill-Stevens, Worta J., Zujewski, Jo Anne , Piccart, Martine , Perez, Edith A. , Dueck, Amylou C. , Hillman, David W. , Wolff, Antonio C. , Gralow, Julie R. , Pritchard, Kathleen I. , Ellard, Susan L. , Azambuja, Evandro de , Zujewski, Jo Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 647-647

10.1200/jco.2014.32.15_suppl.647 Get It

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
Bernath, Albert M., Northfelt, Donald W. , Hou, Xiaonan , Tenner, Kathleen , Tienchaiananda, Piyawan , Flickinger, Lynn M. , Chen, Beiyun, Chen, Helen X., Lingle, Wilma L., Pellegrino, Christine, Sponzo, Robert W., Reinholz, Monica M., Perez, Edith A. , Haluska, Paul , Ballman, Karla V. , Dueck, Amylou C. , Linden, Hannah M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 632-632

10.1200/jco.2014.32.15_suppl.632 Get It

Identification and targeting of M-phase progression downstream of HER2 in trastuzumab-sensitive and -resistant breast cancer cell lines.
Thompson, E. Aubrey , Necela, Brian M. , Carr, Jennifer M., Kachergus, Jennifer M., Serie, Daniel, Asmann, Yan W. , Perez, Edith A. , Kalari, Krishna R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 612-612

10.1200/jco.2014.32.15_suppl.612 Get It

Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer.
Dudenkov, Tanda M., Buzdar, Aman U. , Kubo, Michiaki , Batzler, Anthony , Jenkins, Gregory D. , Pietrzak, Tracy L., Northfelt, Donald W. , Perez, Edith A. , Williard, Clark, Nakamura, Yusuke , Wang, Liewei , Weinshilboum, Richard M. , Ingle, James N. , Robson, Mark E. , Carlson, Erin E. , Fridley, Brooke L. , Goetz, Matthew P. , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 593-593

10.1200/jco.2014.32.15_suppl.593 Get It

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509 Get It

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.
Wiktor, Anne E., Meyer, Reid G., Tenner, Kathleen , Perez, Edith A. , Jenkins, Robert B. , Shah, Meera , Ballman, Karla V. , Ketterling, Rhett P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 523-523

10.1200/jco.2014.32.15_suppl.523 Get It

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-posi
Piccart, Martine , Holmes, Andrew , Baselga, José , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Jackisch, Christian , Láng, István, Smith, Ian E., Boyle, Frances , Gelber, Richard D. , Perez, Edith A. , Azambuja, Evandro de , Dueck, Amylou C. , Zujewski, Jo Anne , Santillana, Sergio, Pritchard, Kathleen I. , Wolff, Antonio C. , Untch, Michael , Xu, Binghe , Gómez, Henry

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2014.32.15_suppl.lba4 Get It

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT a
Pagani, Olivia , Regan, Meredith M. , Walley, Barbara , Láng, István, Burstein, Harold J. , Perez, Edith A. , Ciruelos, Eva, Martino, Silvana, Coates, Alan S. , Gelber, Richard D. , Goldhirsch, Aron, Group, SOFT and TEXT Investigators and International Breast Cancer Study, Fleming, Gini F. , Colleoni, Marco , Gómez, Henry , Tondini, Carlo Alberto , Stearns, Vered , Bonnefoi, Hervé , Geyer, Charles E. , Rabaglio, Manuela , Francis, Prudence A. , Group, SOFT and TEXT Investigators and International Breast Cancer Study

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA1-LBA1

10.1200/jco.2014.32.15_suppl.lba1 Get It